Tandem Diabetes Care has announced its Tandem t:slim X2 insulin pump is now compatible with Abbott鈥檚 FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor.
The early access programme for this integration has already started in the US, with plans to scale the availability in the second half of this year.
With its extended 15-day wear duration, the FreeStyle Libre 3 Plus sensor provides minute-by-minute glucose readings that are directly transmitted to the pump.
This allows the data to be viewed on the t:slim mobile app, offering users access to their present glucose trends.
Powered by the Control-IQ+ technology, the t:slim X2 insulin pump claims to be the newest generation of hybrid closed-loop algorithm of Tandem, which will adjust insulin delivery every five minutes based on predicted glucose levels.
The system’s AutoBolus feature is designed to calculate and deliver correction boluses, which help manage missed meal boluses.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis technology has ease of use and personalisation, and with this new integration, it extends its benefits to a broader range of individuals with diabetes.
Notably, the insulin pump allows users to update features remotely using a personal computer, ensuring that the pump remains equipped with the latest technology throughout its warranty time.
Tandem Diabetes Care chief medical officer Dr聽Jordan Pinsker said: 鈥淒iabetes management is not one-size-fits-all, and it is critical for people living with diabetes to be able to personalise their AID systems to fit their unique healthcare and lifestyle needs.
鈥淭he American Diabetes Association recommends AID systems as the preferred insulin delivery method in people with type 1 and other types of insulin-deficient diabetes, and this integration with Abbott鈥檚 latest generation sensor allows even more CGM users to access the life-changing benefits of our Control-IQ+ technology.鈥�
In February 2025, the US Food and Drug Administration (FDA) cleared Tandem Diabetes Care鈥檚 Control-IQ+ technology, making it available for use by individuals aged 18 and above with type 2 diabetes.
